Evidence map›Paper›PMID 36264931›Full record

ArticlePloS one2022

Readmission rates and risk factors for readmission after transcatheter aortic valve replacement in patients with end-stage renal disease.

Dae Yong Park, Seokyung An, Jonathan M Hanna, Stephen Y Wang, Ana S Cruz-Solbes, Ajar Kochar, Angela M Lowenstern, John K Forrest, Yousif Ahmad, Michael Cleman and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Dae Yong ParkDepartment of Medicine, Cook County Health, Chicago, Illinois, United States of America.ORCID 0000-0002-1486-7452
Seokyung AnDepartment of Biomedical Science, Seoul National University Graduate School, Seoul, Korea.ORCID 0000-0002-1971-1094
Jonathan M HannaDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Stephen Y WangDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Ana S Cruz-SolbesDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Ajar KocharSection of Interventional Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Angela M LowensternDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
John K ForrestSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Yousif AhmadSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Michael ClemanSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Abdulla Al DamlujiSection of Interventional Cardiology, Johns Hopkins University, Baltimore, Maryland, United States of America.
Michael G NannaSection of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0001-5745-1636
Yale University · USBrigham and Women's Hospital · USCook County Health and Hospitals System · USJohns Hopkins University · USSeoul National University · KRVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe sought to examine readmission rates and predictors of hospital readmission following TAVR in patients with ESRD.

backgroundEnd-stage renal disease (ESRD) is associated with poor outcomes following transcatheter aortic valve replacement (TAVR).

methodsWe assessed index hospitalizations for TAVR from the National Readmissions Database from 2017 to 2018 and used propensity scores to match those with and without ESRD. We compared 90-day readmission for any cause or cardiovascular cause. Length of stay (LOS), mortality, and cost were assessed for index hospitalizations and 90-day readmissions. Multivariable logistic regression was performed to identify predictors of 90-day readmission.

resultsWe identified 49,172 index hospitalizations for TAVR, including 1,219 patients with ESRD (2.5%). Patient with ESRD had higher rates of all-cause readmission (34.4% vs. 19.2%, HR 1.96, 95% CI 1.68-2.30, p<0.001) and cardiovascular readmission (13.2% vs. 7.7%, HR 1.85, 95% CI 1.44-2.38, p<0.001) at 90 days. During index hospitalization, patients with ESRD had longer length of stay (mean difference 1.9 days), increased hospital cost (mean difference $42,915), and increased in-hospital mortality (2.6% vs. 0.9%). Among those readmitted within 90 days, patients with ESRD had longer LOS and increased hospital charge, but similar in-hospital mortality. Diabetes (OR 1.86, 95% CI 1.31-2.64) and chronic pulmonary disease (OR 1.51, 95% CI 1.04-2.18) were independently associated with higher odds of 90-day readmission in patients with ESRD.

conclusionPatients with ESRD undergoing TAVR have higher mortality and increased cost associated with their index hospitalization and are at increased risk of readmission within 90 days following TAVR.

Indexed as

Aortic Valve StenosisKidney Failure, ChronicTranscatheter Aortic Valve ReplacementHumansPatient ReadmissionRisk FactorsTime FactorsTreatment Outcome

Identifiers

PMID36264931
PMCPMC9584363
OpenAlexW4306898364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.